Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for enVVeno Medical Corporation (NVNO : NSDQ)

• Company Description    enVVeno Medical Corporation is a medical device company. It focuses in the treatment of venous disease. enVVeno Medical Corporation, formerly known as Hancock Jaffe Laboratories Inc., is based in IRVINE, CA. Number of Employees: 24

• Price / Volume Information    Yesterday's Closing Price: $4.16 Daily Weekly Monthly 20 Day Moving Average: 27,384 shares Shares Outstanding: 9.47 (millions) Market Capitalization: $39.39 (millions) Beta: 1.37 52 Week High: $11.38 52 Week Low: $3.88 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.23% -3.40% 12 Week -8.37% 0.73% Year To Date -36.87% -19.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 70 DOPPLER - IRVINE,CA 92618 USA ph: 949-261-2900 fax: 949-261-2992 None http://www.hancockjaffe.com

• General Corporate Information    Officers Robert Berman - Chief Executive Officer Craig Glynn - Chief Financial Officer Marc H. Glickman - Senior Vice President and Chief Medical Officer Sanjay Shrivastava - Director Matthew M. Jenusaitis - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 29415J106 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/10/22 Share - Related Items Shares Outstanding: 9.47 Most Recent Split Date: 11.00 (0.04:1) Beta: 1.37 Market Capitalization: $39.39 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.53 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.77 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 2.08% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -37.30 12/31/21 - -33.67 09/30/21 - -31.97 ROA 03/31/22 - -35.76 12/31/21 - -32.36 09/30/21 - -30.33 Current Ratio 03/31/22 - 40.67 12/31/21 - 34.83 09/30/21 - 52.06 Quick Ratio 03/31/22 - 40.67 12/31/21 - 34.84 09/30/21 - 52.06 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 5.42 12/31/21 - 5.75 09/30/21 - 6.13 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©